高通量膜蛋白单克隆抗体芯片

Using the proprietary MabArrayTM composed of 100,000 mouse monoclonal antibodies, we have successfully identified a number of novel targets for antibody-drug conjugates (ADC) including a cancer stem cell marker, in lung squamous cell carcinoma (SCC). The mAb116 was found to bind with a sub-nM affinity to this cancer stem cell marker and quickly internalized to the late lysosome after binding to the target. The ADC developed based on mAb116 (termed AMT116, i.e. mAb116-vc-MMAE) showed very potent tumor inhibition in both in vitro cytotoxity and in vivo cell-line derived xenograft (CDX) studies, and its effect was positively correlated with the expression of target. Therefore, the target identified by mAb116 is a cancer stem cell marker and deserves further development as a potential target for the development of ADC or other therapeutics.